1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Molecular Pharmacology (USA), Ltd.

Molecular Pharmacology (USA), Ltd.

MLPH
Molecular Pharmacology (USA), Ltd.US flagOther OTC
0.03
USD
-NaN
- -
643,711.00Market Cap
Molecular Pharmacology (USA), Ltd.
MLPH
(Other OTC)

Recent

price

0.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
-0.02
-0.02
-0.02
-0.02
Book Value per Share
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
-0.02
-0.02
-0.02
-0.02
Tangible Book Value per Share
88
99
- -
112
112
112
112
112
112
112
112
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-1
- -
- -
- -
- -
- -
- -
- -
- -
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
-1
-1
-1
-1
-1
-2
-2
-2
-2
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'14
Jun'14
Sep'15
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
112
112
Market Capitalization
91
56
45

Working Capital

FRC

•

in mil. unless spec.
Mar'14
Jun'14
Sep'15
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
- -
2
Payables & Accruals
2
- -
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.13%
8.71%
Free Cash Flow
- -
14.97%
-48.95%
Net Income, GAAP
- -
9.63%
-44.29%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
Similar Companies
FluoroPharma Medical, Inc. (FPMI)
Dogwood Therapeutics, Inc. (DWTX)
MBX Biosciences, Inc. Common Stock (MBX)
Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
Navidea Biopharmaceuticals, Inc. (NAVBQ)
MedinCell S.A. (MEDCL.PA)
Business
Molecular Pharmacology (USA) Limited (MLPH) is a development-stage pharmaceutical company that develops and commercializes pain and inflammation management products, including the analgesic and anti-inflammatory molecule Tripeptofen for treating everyday pain, available in various dosage forms, formulations, line extensions, and package configurations; it also pursues therapeutic, cosmetic, and cosmeceutical products based on the ThermaLIFE range through an agreement with Dermatology Development Corporation. The company markets its offerings via pharmaceutical distributors and collaborative partnerships in the United States and Europe, operating primarily in Australia and the United States through its subsidiary Molecular Pharmacology Pty. Ltd. Founded in 2002 and headquartered at the Drug Discovery Centre in Leederville, Perth, Australia, Molecular Pharmacology (USA) Limited functions as a subsidiary of PharmaNet Group Limited under the leadership of CEO Jeffrey David Edwards, with minimal operations reflected in zero revenue, a net loss of $105,180 (TTM), and one employee. No significant recent partnerships, funding rounds, acquisitions, product launches, or strategic shifts have been reported in the last 1-2 years, consistent with its dormant shell company status on the OTC Markets.